The Medical Letter on Drugs and Therapeutics
Adapalene-Benzoyl Peroxide (Epiduo) for Acne
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Epiduo gel (Galderma), a fixed-dose combination of adapalene 0.1% (Differin), a synthetic retinoid analog, and benzoyl peroxide (BPO) 2.5%, an oxidizing agent, has been approved by the FDA for topical treatment of acne vulgaris in patients ≥12 years old.

RATIONALE FOR COMBINATION TREATMENT — Since the pathogenesis of acne is multifactorial, combining drugs with different mechanisms of action may enhance efficacy. Topical retinoids are often used in combination with topical or systemic antimicrobials for treatment of inflammatory acne.1 Adapalene modulates epithelial keratinization, inflammation and differentiation of follicular epithelial cells, decreasing formation of comedones and inflammatory lesions. The effect of BPO is primarily due to its bactericidal activity against Propionibacterium acnes. Unlike other topical antimicrobials, it has shown no evidence of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Adapalene-Benzoyl Peroxide (Epiduo) for Acne
Article code: 1310b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian